Conclusions
cardiometabolic syndrome, HFpEF
CARDIOMETABOLIC SYNDROME
Our study investigated the potential therapeutic effects of oral treatment with GGA in a model of the cardiometabolic syndrome. Our findings suggest that GGA treatment can increase HSPB1 and HSPB5 to the myofilaments of cardiomyocytes, and reduce cardiomyocyte stiffness by phosphorylation‐dependent and phosphorylation‐independent mechanisms. These effects may delay the development of impaired LV relaxation in the cardiometabolic syndrome. Taken together, our findings suggest that oral GGA treatment could improve therapy in early HFpEF.